Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for RBSH.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2023 0.00
March 31, 2023 0.00
December 31, 2022 0.00
September 30, 2022 0.00
June 30, 2022 0.00
March 31, 2022 0.00
December 31, 2021 0.00
September 30, 2021 0.00
June 30, 2021 0.50M
March 31, 2021 0.50M
December 31, 2020 0.50M
September 30, 2020 0.00
June 30, 2020 0.005M
March 31, 2020 0.25M
December 31, 2019 0.00
September 30, 2019 0.00
June 30, 2019 0.00
March 31, 2019 0.005M
December 31, 2018 0.025M
September 30, 2018 0.50M
June 30, 2018 0.00
March 31, 2018 0.00
December 31, 2017 0.00
September 30, 2017 0.25M
June 30, 2017 0.09M
Date Value
March 31, 2017 0.195M
December 31, 2016 0.815M
September 30, 2016 0.00
June 30, 2016 0.00
March 31, 2016 0.00
December 31, 2015 2.238M
September 30, 2015 2.261M
June 30, 2015 0.00
March 31, 2015 0.287M
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 3.777M
March 31, 2014 0.00
December 31, 2013 0.00
September 30, 2013 4.645M
June 30, 2013 0.093M
March 31, 2013 1.219M
December 31, 2012 0.8495M
September 30, 2012 0.0625M
June 30, 2012 0.0335M
March 31, 2012 0.3975M
December 31, 2011 0.00
September 30, 2011 0.00
June 30, 2011 2.19M
March 31, 2011 3.413M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 10.49M
Alnylam Pharmaceuticals, Inc. 36.24M
Anika Therapeutics, Inc. -0.701M
Savara, Inc. 0.189M
Vericel Corp. 2.692M